Last reviewed · How we verify
NCT03536182: CIPHER
Trial of Carbon Ion Versus Photon Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer
Withdrawn
Phase 3
Last updated 26 May 2021
What this trial tests
Phase 3 trial testing Carbon Ion Radiation Therapy (CIRT) in Locally Advanced Pancreatic Adenocarcinoma. Withdrawn.
Timeline
29 May 2019
Primary endpoint
1 July 2021
1 July 2021
1 July 2023
Quick facts
| Lead sponsor | University of Texas Southwestern Medical Center |
|---|---|
| Phase | Phase 3 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Start date | 29 May 2019 |
| Primary completion | 1 July 2021 |
| Estimated completion | 1 July 2023 |
| Sites | 2 locations across Japan, United States |
Drugs / interventions tested
- Carbon Ion Radiation Therapy (CIRT)
- Intensity Modulated Radiation Therapy (IMRT)
Conditions studied
- Locally Advanced Pancreatic Adenocarcinoma — all drugs for Locally Advanced Pancreatic Adenocarcinoma →
Sponsor
University of Texas Southwestern Medical Center
Who can join
Adults 18 to 120, any sex, with Locally Advanced Pancreatic Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To determine if carbon ion radiotherapy improves overall survival versus photon therapy in patients with locally advanced, unresectable pancreatic cancer
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Carbon Ion Radiobiology.
Tinganelli W, Durante M. · · 2020 · cited 180× · PMID 33080914 · DOI 10.3390/cancers12103022 -
Carbon Ion Therapy: A Modern Review of an Emerging Technology.
Malouff TD, Mahajan A, Krishnan S, Beltran C, et al · · 2020 · cited 162× · PMID 32117737 · DOI 10.3389/fonc.2020.00082 -
Novel strategies using modern radiotherapy to improve pancreatic cancer outcomes: toward a new standard?
Bouchart C, Navez J, Closset J, Hendlisz A, et al · · 2020 · cited 27× · PMID 32684987 · DOI 10.1177/1758835920936093 -
Carbon ion radiotherapy as definitive treatment in non-metastasized pancreatic cancer: study protocol of the prospective phase II PACK-study.
Liermann J, Naumann P, Hommertgen A, Pohl M, et al · · 2020 · cited 16× · PMID 33004046 · DOI 10.1186/s12885-020-07434-8 -
Is There a Standard Adjuvant Therapy for Resected Pancreatic Cancer?
Fenocchio E, Filippi R, Lombardi P, Quarà V, et al · · 2019 · cited 12× · PMID 31614884 · DOI 10.3390/cancers11101547 -
Pragmatic, Prospective Comparative Effectiveness Trial of Carbon Ion Therapy, Surgery, and Proton Therapy for the Management of Pelvic Sarcomas (Soft Tissue/Bone) Involving the Bone: The PROSPER Study Rationale and Design.
Hoppe BS, Petersen IA, Wilke BK, DeWees TA, et al · · 2023 · cited 10× · PMID 36980545 · DOI 10.3390/cancers15061660 -
Estimating the Number of Patients Eligible for Carbon Ion Radiotherapy in the United States.
Malouff TD, Vallow LA, Seneviratne D, Mahajan A, et al · · 2020 · cited 10× · PMID 33274255 · DOI 10.14338/ijpt-19-00079.1 -
Could Protons and Carbon Ions Be the Silver Bullets Against Pancreatic Cancer?
Huart C, Chen JW, Le Calvé B, Michiels C, et al · · 2020 · cited 8× · PMID 32635552 · DOI 10.3390/ijms21134767
Verify or expand the search:
- PubMed search for NCT03536182
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Locally Advanced Pancreatic Adenocarcinoma
Currently open trials in the same condition.
- NCT07157033 — A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With St · Phase 1, PHASE2 · recruiting
- NCT06861088 — The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer · Phase 3 · recruiting
- NCT06861452 — Phase I/IIa Study: RR001 Administered Following Chemotherapy Cycles for Patients With Locally Advanced Pancreatic Carcin · Phase 1, PHASE2 · recruiting
- NCT06850623 — Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer · Phase 2 · recruiting
- NCT07241663 — Surgery for Locally Unresectable Pancreatic Cancer · recruiting
Other University of Texas Southwestern Medical Center trials
Trials by the same sponsor.
- NCT03849963 — Imaging Oxidative Metabolism and Neurotransmitter Synthesis in the Human Brain · recruiting
- NCT06917183 — Developing Strategies for Implementation and Use of the Operating Room Black Box (ORBB) · NA · not yet recruiting
- NCT05145309 — Value of Potassium Magnesium Citrate in Preventing and Treating Hypertension in African Americans · Phase 2 · not yet recruiting
- NCT06552000 — Pre-operative Tumor Treating Fields in Patients With Resectable Lung Cancer · NA · not yet recruiting
- NCT07387666 — Imaging Acetadote Metabolism in Glioblastoma · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT03536182 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Texas Southwestern Medical Center
- Last refreshed: 26 May 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03536182.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing